[The therapeutic and prophylactic use of Olicard-Retard under outpatient polyclinical conditions in stenocardia patients].
Olicard-Retard, isosorbide-5-mononitrate drug, has been tried in a single daily dose 40 mg in 60 outpatients with angina pectoris. The drug reduced the frequency of anginal attacks and nitroglycerine intake in most of the patients. The antianginal properties were combined with anti-ischemic effects as shown by echocardiography. Side effects (head ache) were mild. Olicard-Retard proved effective in angina of effort both in monotherapy and combined treatment.